Navigation Links
Tested a drug that strengthens the analgesic effect of opioids without increasing constipation
Date:3/31/2014

Scientists from the University of Granada have taken part, alongside the Esteve laboratory, in the development of a new drug that multiplies the analgesic effect of opioids (drugs for treating intense pain), without increasing constipation, one of the most common side-effects of these drugs, among which is morphine.

This important scientific breakthrough has been published in The Journal of Pharmacology and Experimental Therapeutics, and has been chosen as its outstanding article in the month of January. So far, the University of Granada researchers have published the results from testing this molecule on mice.

Opium derivates have been used since ancient times to treat pain. Currently, these and similar products (opioids) are the drugs used to treat various types of intense pain, such as post-operatory pain, cancer pain or internal-organ pain. The prolonged use of opioids causes strong constipation, which is a substantial drawback to their administration, since it substantially diminishes patient well-being.

The recently-published article proves that S1RA, a drug that blocks the sigma-1 receptor, manages to multiply solely the beneficial effect of the opioids; that is, their pain-killing properties.

The sigma-1 receptor is a very small protein that acts as a neuro-modulator, physically linking to other proteins (among which are the opioid receptors) and modifying their function.

As Enrique Cobos del Moral, one of the authors and a researcher at the University of Granada Institute of Neuroscience, explains, opioids are basically "centrally-acting" drugs; that is, they act directly upon the brain and the spinal medula. However, when opioids are associated with sigma-1 receptor blockers, their pain-killing effects are brought about by acting upon other areas; specifically, on the peripheral nervous system. From this, it is deduced that the sigma-1 receptor is a biological brake that prevents peripheral opioid analgesia, and that this brake can be eliminated by pharmacological treatment so as to increase the pain-killing power of opioids.

This scientific breakthrough is of huge importance for the well-being of patients suffering from pain, since, in the short term, it will allow the development of more efficient painkillers with fewer side-effects.

Esteve is working on the development of this medication, which is currently in Clinical Phase II


'/>"/>

Contact: Enrique J. Cobos del Moral
ejcobos@ugr.es
34-958-243-538
University of Granada
Source:Eurekalert  

Related medicine news :

1. Study questions anti-cancer mechanisms of drug tested in clinical trials
2. Data show drug being tested to reduce cardiovascular events increased risk of heart attack
3. Kirkman® Adds New Comprehensive Antioxidant to Ultra Tested® Product Line: Antioxidant/Cell Protect – Hypoallergenic
4. Brain Research Labs Brain Health And Performance News: Pioneer in the Field of Cognitive Performance and Health Succeeds with Clinically-Tested Natural Solutions
5. Fully Dissolvable, Temporary Stent for Opening Heart Artery Blockages Now Being Tested at The Mount Sinai Medical Center
6. Magellan Echo to Be Tested by Heart Rate Watch Company
7. Baron and Budd Supports the Newest Drug Being Tested for Mesothelioma Treatment
8. This Tested and Proven Ingredient Should be in Every Adults Daily Regime for Younger Skin, Says Sublime Beauty
9. SafeToSleep Baby Monitor Wins Parent Tested Parent Approved (PTPA) Award
10. Through New Innovative Measures, Highly Pathogenic Microbes Will Now Be Tested Clinically, Strengthening The Front Line In The Fight Against Food-Borne Illness
11. Handheld device for detecting counterfeit and substandard medicines tested by PQM
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tested a drug that strengthens the analgesic effect of opioids without increasing constipation
(Date:5/23/2019)... ... May 23, 2019 , ... Hoban Law Group is proud to be partnering ... “It is essential to help educate the public about the most sweeping cannabis reform ... to do so than Times Square,” said Hoban Law Group Founder & President Bob ...
(Date:5/23/2019)... ... May 23, 2019 , ... Join Dr. Ashok Srivastava, CEO & CMO ... of Data Sciences at OmniComm Systems, Inc. , in a live webinar ... learn about the benefits of visual patient profiles. Together, the two speakers bring years ...
(Date:5/23/2019)... (PRWEB) , ... May 23, 2019 , ... ... line of nootropic products, has recently partnered with Emerson Ecologics. Qualia Mind, Qualia ... their online Practitioner dispensary platform Wellevate. With Emerson’s extensive nearly 40 year history ...
(Date:5/22/2019)... , ... May 22, 2019 , ... ... 55% between Q1 of 2018 and Q1 of 2019 due to the hyper-vigilance ... Solutions (HRS). In addition to this steep reduction in readmissions, Community VNA has ...
(Date:5/22/2019)... ... 22, 2019 , ... Hypertrophic cardiomyopathy (HCM) is ... within the general population. Hypertrophic cardiomyopathy occurs if heart muscle cells enlarge and ... muscle can make it harder for the heart to pump blood. The Society ...
Breaking Medicine News(10 mins):
(Date:5/23/2019)... ... 23, 2019 , ... Over 68% of healthcare organizations have adopted a clinical ... custom research division of Worldwide Business Research , the global leader in B2B ... offer clinical aromatherapy report positive (44%) or highly positive (22%) patient responses. , Produced ...
(Date:5/23/2019)... ... May 23, 2019 , ... ZVOX Audio ... of the AccuVoice AV50 Noise-Cancelling Headphone. The latest addition to the ZVOX family ... the AV50 is the first high-performance noise cancelling headphone from a major audio ...
(Date:5/23/2019)... MINNEAPOLIS (PRWEB) , ... May 23, 2019 , ... ... system (MD QMS) software platform, is bringing their 2019 True Quality Roadshow, ... on June 13 at the Watson Block Event Center & Venue. , The ...
Breaking Medicine Technology: